Leap Therapeutics Secures $58.9 Million for Digital Asset Strategy
Boston, Monday, 6 October 2025.
Leap Therapeutics raised $58.9 million through a private placement led by Winklevoss Capital to launch a digital asset treasury strategy, highlighting innovation in biotech financing.
Biotechnology Meets Digital Finance
Leap Therapeutics, a key player in the biotechnology sector, has strategically secured $58.9 million through a private placement led by Winklevoss Capital to launch a digital asset treasury strategy. This initiative marks a significant leap in integrating digital finance into the biotech industry, indicating a shift towards innovative funding mechanisms that enhance financial resilience and operational flexibility [1].
Strategic Financial Innovation
The private placement includes the issuance of approximately 95.8 million shares of common stock or pre-funded warrants, alongside warrants to purchase an additional 71.9 million shares at an exercise price of $0.5335 per share. The total exercise price per unit stands at $0.61439 [2]. Winklevoss Capital, known for its pioneering investments in frontier technologies, not only provides financial backing but also strategic support, ensuring the successful implementation of Leap’s digital asset treasury strategy [2][3].
Impact on Healthcare Solutions
A significant portion of the newly secured capital will be allocated to advancing Leap’s therapeutic programs, including FL-501 and sirexatamab. The latter, recently completing a Phase 2 trial for colorectal cancer patients, will have its findings presented at the European Society for Medical Oncology Congress on October 19, 2025, in Berlin, Germany [1][2]. This funding is pivotal in accelerating the development of these critical healthcare solutions, underscoring the intersection of financial innovation and medical advancement.
Corporate Governance and Strategic Growth
Aligning with the new funding strategy, Leap Therapeutics plans to expand its Board of Directors to 12 members, granting Winklevoss Capital the right to nominate two directors, including the chairperson [1][3]. This expansion reflects a strategic approach to governance, enhancing the company’s ability to navigate the complex biotech landscape and optimize its operational and financial strategies. The closing of the private placement is anticipated around October 8, 2025, subject to customary conditions [2].